On 12- 14 November 2019 ReSViNET Foundation will host its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!

PAPER OF THE MONTH - September 2019

DS-Cav1 beats previous subunit RSV vaccines
Crank MC, Ruckwardt TJ, Chen M, Morabito1 KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT,  Schwartz RM, Kueltzo1 L, Cooper JW, Chen P, Stein JA, Carlton1 K, Gall JG, Nason MC, Kwong PD, Chen1 GL, Mascola JR,McLellan JS, Ledgerwood JE, Graham BS, the VRC 317 Study Team
​
This RSV subunit vaccine has smoothly passed the first hurdle in clinical development. DS-Cav1 is stabilized trimer of the prefusion conformation of the RSV-F protein. The vaccine was clinically evaluated by the same researchers of the Vaccine Research Center (VRC) of the Nation Institute of Health (NIH) only a few years after demonstrating the existence of the prefusion and postfusion RSV-F variants. Immunogenicity of this apparently safe vaccine was tested in a diverse group of 40 healthy adults up to 12 weeks after vaccination. Remarkably, the vaccine resulted in an increase in neutralization that was larger than the increase in binding to RSV F. Twelve weeks after vaccination, neutralization of RSV A was still increased 5 to 10-fold, while a 3 to 5-fold increase in RSV B neutralization was observed. The boost of neutralization was mediated by antibodies against preF and shared pre/post F epitopes, but not by antibodies against epitopes only present at postF. Using preF and postF probes, the authors show that the vaccine elicits a boost in memory preF B-cells, but not postF B-cells. Taken together, DS-Cav1 shows superiority to previous subunit vaccines by inducing higher levels of neutralizing antibodies with a relatively low induction of non-neutralizing antibodies.

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

RESPIRATORY SYNCYTIAL VIRUS AND CHILD PNEUMONIA WEBINAR

Dr. Ting Shi (University of Edinburgh): Global disease burden estimate of RSV in young children
Dr. Marijke Proesmans (Katholieke Universiteit Leuven): RSV therapeutics
Dr. Keith Klugman (Director, Pneumonia, Bill&Melinda Gates Foundation): RSV immunization and future directions
Dr. Louis Bont (Chairman ReSViNET Foundation): RSV clinical presentation and disease severity​
Visual
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
 NOTE: Please download this slide deck from the SlideShare platform to view.
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.

ABOUT RESVINET FOUNDATION

ReSViNET Global partners